Abstract: Methods and kits for identifying neurological conditions in a patient by determining a level of expression of dynactin subunit p62 are disclosed. The neurological conditions may include, for example, Alzheimer's Disease (AD) without cerebral amyloid angiopathy (CAA).

Abstract: An automatic method for detection and quantification of localized sources of magnetic susceptibility in images using a computer with instructions for a parameter module; an image input and filtering module; a second image filtering module; and a pattern quantification module.

Abstract: A substance for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system; and a vehicle for transporting the inhibitor into the cerebrovasculature; where the inhibition by the inhibitor is sufficient to decrease the incidence of or to prevent the incidence of cytolysis of the smooth muscle cells. A method for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising: a) identifying a patient with a cerebral amyloid angiopathy related condition or disease; b) providing one or more than one substance that comprises an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system, c) administering one or more than one dose of the one or more than one substance to the patient.

Abstract: An automatic method for detection and quantification of localized sources of magnetic susceptibility in images using a computer with instructions for a parameter module; an image input and filtering module; a second image filtering module; and a pattern quantification module.

Abstract: A substance for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system; and a vehicle for transporting the inhibitor into the cerebrovasculature; where the inhibition by the inhibitor is sufficient to decrease the incidence of or to prevent the incidence of cytolysis of the smooth muscle cells. A method for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising: a) identifying a patient with a cerebral amyloid angiopathy related condition or disease; b) providing one or more than one substance that comprises an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system, c) administering one or more than one dose of the one or more than one substance to the patient.

Abstract: An automatic method for detection and quantification of localized sources of magnetic susceptibility in images using a computer with instructions for a parameter module; an image input and filtering module; a second image filtering module; and a pattern quantification module.

Abstract: Methods and kits for identifying and/or monitoring neurological conditions in a patient using ratios of biomarkers are disclosed. The neurological conditions may include, for example, Alzheimer's disease or mild cognitive impairment. The particular biomarkers that may be useful in identifying and/or monitoring neurological conditions may include, for example, biliverdin reductase, biliverdin reductase, estrogen receptor alpha, superoxide dismutase, S100A7, hemeoxygenase 1, matrix metalloproteinase 9 and platelet derived growth factor receptor. In particular, ratios of these biomarkers are useful.

Abstract: Methods and kits for identifying neurological conditions in a patient by determining a level of expression of dynactin subunit p62 are disclosed. The neurological conditions may include, for example, Alzheimer's Disease (AD) without cerebral amyloid angiopathy (CAA).

Abstract: An automatic method for detection and quantification of localized sources of magnetic susceptibility in images using a computer with instructions for a parameter module; an image input and filtering module; a second image filtering module; and a pattern quantification module.

Abstract: A method to quantify iron content or effective diameter of a localized iron source in an anatomical region of a subject is provided herein. The first step is to obtain a phase image from a magnetic resonance scan of the anatomical region of the subject. The next step is identifying a dipole pattern in the phase image corresponding to a localized iron source in the anatomical region. One or more than one image parameter of the dipole pattern is then measured and related to the iron content of the localized iron source.